Okan Kadir Nohut

Dr. Okan Kadir Nohut

orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 November 2021 in Nutrients
Verified
Journal Article
Open access
PDF file
MGMustafa Sait Gönen
Mustafa Sait Gönen
MAMerve Alaylıoğlu
Merve Alaylıoğlu
EDEmre Durcan
Emre Durcan
YÖYusuf Özdemir
Yusuf Özdemir
SŞSerdar Şahin
Serdar Şahin
EDErdinç Dursun
Erdinç Dursun
Background: We aimed to establish an acute treatment protocol to increase serum vitamin D, evaluate the effectiveness of vitamin D3 supplementation, and reveal the potential mechanisms in COVID-19. Methods: We retrospectively analyzed the data of 867 COVID-19 cases. Then, a prospective study was conducted, including 23 healthy individuals and 210 cases. A total of 163 cases had vitamin D supplementation, and 95 were followed for 14 days. Clinical outcomes, routine blood biomarkers, serum levels of vitamin D metabolism, and action mechanism-related parameters were evaluated. Results: Our treatment protocol increased the serum 25OHD levels significantly to above 30 ng/mL within two weeks. COVID-19 cases (no comorbidities, no vitamin D treatment, 25OHD <30 ng/mL) had 1.9-fold increased risk of having hospitalization longer than 8 days compared with the cases with comorbidities and vitamin D treatment. Having vitamin D treatment decreased the mortality rate by 2.14 times. The correlation analysis of specific serum biomarkers with 25OHD indicated that the vitamin D action in COVID-19 might involve regulation of INOS1, IL1B, IFNg, cathelicidin-LL37, and ICAM1. Conclusions: Vitamin D treatment shortened hospital stay and decreased mortality in COVID-19 cases, even in the existence of comorbidities. Vitamin D supplementation is effective on various target parameters; therefore, it is essential for COVID-19 treatment.

3 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
RSRabia Can Sarinoglu
Rabia Can Sarinoglu
SOSeyhan Ordekci
Seyhan Ordekci
ŞGŞerife Yılmaz Gürbüz
Şerife Yılmaz Gürbüz
GOGunes Ozcolpan
Gunes Ozcolpan
GCGulden Celik
Gulden Celik
Numerous vaccines have been generated to decrease the morbidity and mortality of COVID-19. This study aims to evaluate the immunogenicity of the heterologous boosts by BioNTech against homologous boosts by CoronaVac at three-month intervals in two health care worker (HCW) cohorts, with or without prior COVID-19, for one year post-vaccination. This is a prospective cohort study in which the humoral responses of 386 HCWs were followed-up longitudinally in six main groups according to their previous COVID-19 exposure and vaccination status. Anti-SARS-CoV-2 spike-RBD total antibody levels were measured and SARS-CoV-2 neutralization antibody (NAbs) responses against the ancestral Wuhan and the Omicron variant were evaluated comparatively using international standard serum for Wuhan and Omicron, as well as with the aid of a conversion tool. The anti-SARS-CoV-2 spike-RBD total Ab and Nab difference between with and without prior COVID-19, three months after two-dose primary vaccination with CoronaVac, was statistically significant (p = 0.001). In the subsequent follow-ups, this difference was not observed between the groups. Those previously infected (PI) and non-previously infected (NPI) groups receiving BioNTech as the third dose had higher anti-SARS-CoV-2 spike total Ab levels (14.2-fold and 17.4-fold, respectively, p = 0.001) and Nab responses (against Wuhan and Omicron) than those receiving CoronaVac. Ab responses after booster vaccination decreased significantly in all groups at the ninth-month follow-up (p < 0.05); however, Abs were still higher in all booster received groups than that in the primary vaccination. Abs were above the protective level at the twelfth-month measurement in the entire of the second BioNTech received group as the fourth dose of vaccination. In the one-year follow-up period, the increased incidence of COVID-19 in the groups vaccinated with two or three doses of CoronaVac compared with the groups vaccinated with BioNTech as a booster suggested that continuing the heterologous CoronaVac/BioNTech vaccination, revised according to current SARS-CoV-2 variants and with at least a six-month interval booster would be an effective and safe strategy for protection against COVID-19, particularly in health care workers.

2 July 2022 in Rheumatology International
Verified
Journal Article
Closed access
PDF file
AOAyse Ozdede
Ayse Ozdede
ONOkan Kadir Nohut
Okan Kadir Nohut
ZAZeynep Atli
Zeynep Atli
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
SGSabriye Guner
Sabriye Guner
ESEmire Seyahi
Emire Seyahi

3 December 2021 in Balkan Medical Journal
Verified
Journal Article
Open access
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
MKMert Ahmet Kuskucu
Mert Ahmet Kuskucu
HEHazal Erdem
Hazal Erdem
DSDevrim Saribal
Devrim Saribal
SYSEDA SALMAN YILMAZ
SEDA SALMAN YILMAZ
KMKenan Midilli
Kenan Midilli
Background: Widespread and effective use of molecular diagnostic tests is indispensable for protecting public health and containing the severe respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. More than 1 year into the pandemic, as resources have reached a point of depiction, grouping samples in pools of certain sizes appears to be a reasonable method to reduce both the costs and the processing time without necessitating additional training, equipment, or materials. Aims: To assess whether the pooling strategy that was used in past outbreaks and is used in blood tests prior to transfusion for screening large populations can also be used in SARS CoV-2 tests. Study Design: Diagnostic accuracy study. Methods: This prospective study was conducted with 2815 samples, sent to the coronavirus disease 2019 (COVID-19) Laboratory of our hospital between February 12 and 21, 2021, to be tested for the presence of SARS-CoV-2. The samples were examined individually and in pools of live 100 mu l taken from each sequential sample, using 3 different SARS-CoV-2 reverse transcription-polymerase chain reaction (RT-PCR) kits. the Allplex (TM) 2019-nCoV Assay kit (Seegene, Republic of Korea), the GeneMAP (TM) 2019-nCoV detection V.3 kit (GenMark, TOrkiye), and the Bio-Speedy (TM) SARS-CoV-2 Double Genetm (TM) RT-qPCR kit (Bioeksen. Turkiye) on the BioRAD CFX96 (TM) Touch (Bio-Rad Laboratories Inc., Hercules, CA, USA) platform available in our laboratory. Results: Following the extraction of serial dilutions prepared from the SARS-CoV-2 RNA positive (cycle of threshold: 20) sample, the standard curves of RT-PCR were analyzed. By evaluating the efficiency (E) values, all 3 kits showed high sensitivity and similar results; while the highest level was detected with the Allplex (TM) 2019-nCoV Assay kit in the nucleocapsid (N) gene (F: 124%), the lowest was detected with the Double Gene (TM) RT-qPCR kit in the N and ORF lab genes (E: 90%). Of the samples included in the study, only 1 positive sample with low viral load was found to be negative when studied by pooling. The total number of kits to be used in pooled tests and then to individually retest the 5 samples in positive pools was calculated as 827 and the savings rate as 69.91% (1968/2815). Conclusion: The pooling strategy is an effective approach to extend the inspect of limited testing resources and reagents available in certain periods of the COVID-19 pandemic. Testing by pooling samples requires improvement of RNA extraction methods and careful monitoring of RT-PCR test sensitivity to avoid missing low-positive entities. Therefore, based on the prevalence of COVID-19 in their regions, laboratories should conduct their own validation of pooling studies for RNA extraction and amplification methods they use.

31 August 2021 in Infectious Diseases and Clinical Microbiology
Verified
Journal Article
Closed access
MKMert Ahmet Kuskucu
Mert Ahmet Kuskucu
YTYeşim Tuyji Tok
Yeşim Tuyji Tok
ONOkan Kadir Nohut
Okan Kadir Nohut
ZOZarifa Orta
Zarifa Orta
EYEbru Yücebag
Ebru Yücebag
KMKenan Midilli
Kenan Midilli
Keeping track of SARS-CoV-2 variants of concern (VOC) is crucial to inform public health efforts and limiting the ongoing pandemic. Here, we describe the first detection of SARS-CoV-2 P.1 lineage in Turkey. The fact that new variants can be detected in every geography of the world indicates the need for more whole genome sequencing in order to better understand virus dynamics and take earlier action. Keywords: SARS-CoV-2, P.1 lineage, Variant of Concern (VOC), mutations

1 June 2018 in Annals of the Rheumatic Diseases
Verified
Journal Article
Open access
PDF file
SES.N. Esatoglu
S.N. Esatoglu
FMFatma Akkoc Mustafayev
Fatma Akkoc Mustafayev
YOY. Ozguler
Y. Ozguler
FOF. Ozbakir
F. Ozbakir
ONOkan Kadir Nohut
Okan Kadir Nohut
GHG. Hatemi
G. Hatemi
Background Immunogenicity of anti-TNFs has been recognised as an important problem that may cause loss of efficacy and adverse events such as infusion reactions. Anti-TNFs are being increasingly used among patients with Behçet’s syndrome (BS). Objectives We aimed to investigate the prevalence of anti-drug antibodies against infliximab (IFX) in patients with BS together with controls. Methods We collected serum samples from 66 consecutive BS patients (51 M, 15 F and mean age 37±9 years) who were treated with IFX. IFX was used for eye involvement in 43, vascular involvement in 12, nervous system involvement in 8 and arthritis in 2 patients. Additionally, 53 ankylosing spondylitis (AS), 25 Crohn’s disease (CD) and 27 rheumatoid arthritis (RA) patients, and 31 healthy subjects were included as controls. We included patients who had received at least 4 cycles of IFX. Samples were collected just before an infusion, stored at −80o C until analysis, and serum IFX trough levels and anti-IFX antibodies were measured by ELISA at the same time. We used a cut-off value of 1 µg/mL for serum IFX trough level, extrapolating from RA studies. After serum sampling, we continued to follow up patients. Results Anti-IFX antibodies were detected in 4 (6%) BS, 5 (18.5%) RA, 3 (12%) CD, and 1 (%2) AS patient, and in none of the healthy subjects. The mean number of IFX cycles was 19±14 in BS, 21±13 in RA, 19±21 in CD, and 33±18 in AS patients. Allergic reactions had occurred in 9 (14%) BS, 6 (22%) RA, 5 (20%) CD, and 4 (7.5%) AS patients. 3/6 RA patients and 3/5 CD patients who had experienced an allergic reaction had anti-IFX antibodies whereas none of BS and AS patients did. The median serum IFX trough level was significantly lower in patients with anti-IFX antibodies compared to those without antibodies (2.32 (IQR: 0.6–3.6) vs 3.35 (IQR: 1.63–5.6; p=0.019). The serum IFX trough level was lower than the cut off value in 6/13 patients with anti-IFX antibodies and in 25/158 without anti-IFX antibodies (46% vs 16%; p=0.015). We were able to get samples before at least 2 consecutive infusions in 27 BS patients and the presence of anti-IFX antibodies was consistent across the samples in all of these patients. We were able to get samples before the infusion and at week 2 in 5 BS patients. Serum IFX level was below 1 µg/mL before IFX and above 1 µg/mL at week 2 in all of these 5 patients. During a median follow up of 1.5 years, 2/4 BS patients with anti-IFX antibodies had flares. Among the 62 patients without anti-IFX antibodies, 49 are still on IFX and IFX was stopped due to remission in 12 and due to infusion reaction in one patient. Overall, 5 infusion reactions occurred during the follow up (4 without anti-IFX antibodies and 1 with anti-IFX antibodies; 6.5% vs 25%). Conclusions Immunogenicity does not seem to be an important problem in BS patients treated with IFX. The frequency of anti-IFX antibodies was lower than RA and CD patients. This might be related to concomitant immunosuppressive and corticosteroid use among BS patients. The presence of anti-IFX antibodies may not be associated with efficacy loss in BS. However, longer follow-up is needed to make that statement as BS has a relapsing-remitting course. Disclosure of Interest None declared